The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
作者信息
Avila Jorge, Leone José Pablo
机构信息
Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA.
Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
出版信息
Ann Transl Med. 2023 Jan 15;11(1):27. doi: 10.21037/atm-22-5266. Epub 2023 Jan 6.
Abstract
摘要
相似文献
1
The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.赛托珠单抗戈维汀在激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中的作用。
Ann Transl Med. 2023 Jan 15;11(1):27. doi: 10.21037/atm-22-5266. Epub 2023 Jan 6.
2
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.戈沙妥珠单抗用于激素受体阳性和三阴性乳腺癌
Mol Cell Pharmacol. 2023;15(1):1-5.
3
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.Sacituzumab govitecan：一种新型抗体药物偶联物的过去、现在和未来及未来展望。
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
4
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.使用 sacituzumab govitecan 治疗转移性三阴性乳腺癌。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1303-1311. doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22.
5
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.注射用戈沙妥珠单抗：三阴性乳腺癌的突破性靶向治疗药物。
Expert Rev Anticancer Ther. 2019 Aug;19(8):673-679. doi: 10.1080/14737140.2019.1654378. Epub 2019 Aug 19.
6
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.转移性三阴性乳腺癌且尿苷二磷酸葡萄糖醛酸转移酶家族1成员A1代谢不良基因型患者接受戈沙妥珠单抗治疗后发生中性粒细胞减少的病例报告
J Oncol Pharm Pract. 2022 Apr;28(3):710-716. doi: 10.1177/10781552211057486. Epub 2021 Nov 11.
7
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.注射用戈沙妥珠单抗治疗转移性三阴性乳腺癌的临床概述和潜在毒性的管理。
Oncologist. 2021 Oct;26(10):827-834. doi: 10.1002/onco.13878. Epub 2021 Jul 10.
8
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.注射用戈沙妥珠单抗：一种用于治疗难治性、转移性三阴性乳腺癌的抗体药物偶联物。
Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17.
9
Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer.戈沙妥珠单抗治疗难治性三阴性转移性乳腺癌
J Adv Pract Oncol. 2021 Sep;12(7):747-752. doi: 10.6004/jadpro.2021.12.7.8. Epub 2021 Sep 1.
10
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.ASCENT研究的通俗易懂总结：戈沙妥珠单抗治疗转移性三阴性乳腺癌
Future Oncol. 2021 Oct 1;17(30):3911-3924. doi: 10.2217/fon-2021-0868. Epub 2021 Sep 1.
本文引用的文献
1
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].[中国乳腺癌抗体药物偶联物毒性管理专家共识]
Zhonghua Zhong Liu Za Zhi. 2022 Sep 23;44(9):913-927. doi: 10.3760/cma.j.cn112152-20220521-00360.
2
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.Sacituzumab govitecan：一种新型抗体药物偶联物的过去、现在和未来及未来展望。
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
3
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.Sacituzumab Govitecan 用于激素受体阳性/人表皮生长因子受体 2 阴性转移性乳腺癌。
J Clin Oncol. 2022 Oct 10;40(29):3365-3376. doi: 10.1200/JCO.22.01002. Epub 2022 Aug 26.
4
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.临床用药及获得性他莫昔芬耐药对乳腺癌细胞中 Trop-2 表达的改变。
Breast Cancer. 2022 Nov;29(6):1076-1087. doi: 10.1007/s12282-022-01389-3. Epub 2022 Jul 27.
5
Sacituzumab govitecan in triple-negative breast cancer.戈沙妥珠单抗治疗三阴性乳腺癌
Ann Transl Med. 2022 Jun;10(11):647. doi: 10.21037/atm-22-813.
6
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.抗体药物偶联物：跨肿瘤组织学的智能化疗递送
CA Cancer J Clin. 2022 Mar;72(2):165-182. doi: 10.3322/caac.21705. Epub 2021 Nov 12.
7
Oncogene-mediated metabolic gene signature predicts breast cancer outcome.癌基因介导的代谢基因特征可预测乳腺癌预后。
NPJ Breast Cancer. 2021 Oct 28;7(1):141. doi: 10.1038/s41523-021-00341-6.
8
Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis.用于免疫组织化学分析的新型抗TROP2单克隆抗体TrMab-29的建立。
Biochem Biophys Rep. 2021 Jan 12;25:100902. doi: 10.1016/j.bbrep.2020.100902. eCollection 2021 Mar.
9
Development and characterization of TrMab‑6, a novel anti‑TROP2 monoclonal antibody for antigen detection in breast cancer.开发和鉴定 TrMab-6，一种新型抗 TROP2 单克隆抗体，用于检测乳腺癌中的抗原。
Mol Med Rep. 2021 Feb;23(2). doi: 10.3892/mmr.2020.11731. Epub 2020 Dec 10.
10
HER2-Mediated Internalization of Cytotoxic Agents in Amplified or Mutant Lung Cancers.HER2 介导的扩增或突变肺癌细胞内细胞毒性药物的内化。
Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25.
Zotero 插件